Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Todd M BauerArmando Santoro Chia-Chi LinIgnacio Garrido-LagunaMarkus JoergerRichard GreilAnna SpreaficoThomas YauMaria-Elisabeth GoebelerMarie Luise Hütter-KrönkeAntonella PerottiPierre-Eric JuifDarlene LuLouise BarysViviana CremascoMarc PelletierHelen EvansClaire FabreToshikiko Doi

Published in: Journal for immunotherapy of cancer (2023)

NCT02947165.

Keyphrases

monoclonal antibody
open label
clinical trial
phase ii
transforming growth factor
squamous cell carcinoma
cross sectional
signaling pathway
childhood cancer